Hybrid cancer drug could be resistance-resistant
Page 1 of 1
Hybrid cancer drug could be resistance-resistant
A team of cancer researchers led by scientists at UC San Francisco and Memorial Sloan Kettering Cancer Center demonstrated in human cells and mouse models that a first-of-its-kind hybrid drug can outsmart drug-resistant cancers. The new drug physically yokes together two existing drugs against a common cancer pathway into a single molecule, generating a double-blow that blocked the resistance cancer cells otherwise develop to either drug on its own.
The researchers, who published their finding online on May 18, 2016 in the journal Nature, hope that their new approach will lead to a whole class of new therapies that keep cancer at bay much longer and improve patient survival.
"Every time we find a new drug target against cancer, we go through one, two, three generations of drugs as the cancer keeps evolving resistance," said study co-senior author Kevan Shokat, Ph.D., professor and vice-chair of the department of cellular and molecular pharmacology at UCSF. "What we really wanted to do was get out ahead of this cycle of resistance."
Researchers unravel mechanisms of drug resistance in common cancer pathway
Precision medicine approaches to cancer, which involve targeting the specific mutations driving an individual patient's disease, run the risk of promoting treatment-resistant tumors by killing off drug-sensitive cancer cells and allowing a minority of mutant, drug-resistant cells to thrive in their place.
Mutations driving over-activation of the protein mTOR—a key molecule regulating cellular growth, division, proliferation, and other important functions—are common factors of many different cancers, making mTOR a key target for anti-tumor therapies. The drug rapamycin and similar therapies that interfere with mTOR's function (such as everolimus, or Afinitor, and temsirolimus, also known as Torisel) have been approved for the treatment of a several cancers, including kidney cancer, pancreatic neuroendocrine tumors, and advanced breast cancer.
Unfortunately, tumors treated with these first-generation mTOR inhibitors often evolve resistance to these drugs. Second-generation mTOR inhibitors, which work by jamming mTOR's ATP site – it's molecular "engine"—are currently in clinical trials, but tumors will assuredly evolve resistance to these drugs too in time, researchers say.
Members of Shokat's laboratory, in collaboration with the researchers in the lab of co-senior author Neal Rosen, M.D., Ph.D., the Enid A. Haupt Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center, began to search for new approaches to attacking these cancers that might avoid the trap of resistance.
Read more at: http://phys.org/news/2016-05-hybrid-cancer-drug-resistance-resistant.html#jCp
The researchers, who published their finding online on May 18, 2016 in the journal Nature, hope that their new approach will lead to a whole class of new therapies that keep cancer at bay much longer and improve patient survival.
"Every time we find a new drug target against cancer, we go through one, two, three generations of drugs as the cancer keeps evolving resistance," said study co-senior author Kevan Shokat, Ph.D., professor and vice-chair of the department of cellular and molecular pharmacology at UCSF. "What we really wanted to do was get out ahead of this cycle of resistance."
Researchers unravel mechanisms of drug resistance in common cancer pathway
Precision medicine approaches to cancer, which involve targeting the specific mutations driving an individual patient's disease, run the risk of promoting treatment-resistant tumors by killing off drug-sensitive cancer cells and allowing a minority of mutant, drug-resistant cells to thrive in their place.
Mutations driving over-activation of the protein mTOR—a key molecule regulating cellular growth, division, proliferation, and other important functions—are common factors of many different cancers, making mTOR a key target for anti-tumor therapies. The drug rapamycin and similar therapies that interfere with mTOR's function (such as everolimus, or Afinitor, and temsirolimus, also known as Torisel) have been approved for the treatment of a several cancers, including kidney cancer, pancreatic neuroendocrine tumors, and advanced breast cancer.
Unfortunately, tumors treated with these first-generation mTOR inhibitors often evolve resistance to these drugs. Second-generation mTOR inhibitors, which work by jamming mTOR's ATP site – it's molecular "engine"—are currently in clinical trials, but tumors will assuredly evolve resistance to these drugs too in time, researchers say.
Members of Shokat's laboratory, in collaboration with the researchers in the lab of co-senior author Neal Rosen, M.D., Ph.D., the Enid A. Haupt Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center, began to search for new approaches to attacking these cancers that might avoid the trap of resistance.
Read more at: http://phys.org/news/2016-05-hybrid-cancer-drug-resistance-resistant.html#jCp
Guest- Guest
Re: Hybrid cancer drug could be resistance-resistant
Good news. Let's hope this works and helps thousands of people.
eddie- King of Beards. Keeper of the Whip. Top Chef. BEES!!!!!! Mushroom muncher. Spider aficionado!
- Posts : 43129
Join date : 2013-07-28
Age : 25
Location : England
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Mar 18, 2023 12:28 pm by Ben Reilly
» TOTAL MADNESS Great British Railway Journeys among shows flagged by counter terror scheme ‘for encouraging far-right sympathies
Wed Feb 22, 2023 5:14 pm by Tommy Monk
» Interesting COVID figures
Tue Feb 21, 2023 5:00 am by Tommy Monk
» HAPPY CHRISTMAS.
Sun Jan 01, 2023 7:33 pm by Tommy Monk
» The Fight Over Climate Change is Over (The Greenies Won!)
Thu Dec 15, 2022 3:59 pm by Tommy Monk
» Trump supporter murders wife, kills family dog, shoots daughter
Mon Dec 12, 2022 1:21 am by 'Wolfie
» Quill
Thu Oct 20, 2022 10:28 pm by Tommy Monk
» Algerian Woman under investigation for torture and murder of French girl, 12, whose body was found in plastic case in Paris
Thu Oct 20, 2022 10:04 pm by Tommy Monk
» Wind turbines cool down the Earth (edited with better video link)
Sun Oct 16, 2022 9:19 am by Ben Reilly
» Saying goodbye to our Queen.
Sun Sep 25, 2022 9:02 pm by Maddog
» PHEW.
Sat Sep 17, 2022 6:33 pm by Syl
» And here's some more enrichment...
Thu Sep 15, 2022 3:46 pm by Ben Reilly
» John F Kennedy Assassination
Thu Sep 15, 2022 3:40 pm by Ben Reilly
» Where is everyone lately...?
Thu Sep 15, 2022 3:33 pm by Ben Reilly
» London violence over the weekend...
Mon Sep 05, 2022 2:19 pm by Tommy Monk
» Why should anyone believe anything that Mo Farah says...!?
Wed Jul 13, 2022 1:44 am by Tommy Monk
» Liverpool Labour defends mayor role poll after turnout was only 3% and they say they will push ahead with the option that was least preferred!!!
Mon Jul 11, 2022 1:11 pm by Tommy Monk
» Labour leader Keir Stammer can't answer the simple question of whether a woman has a penis or not...
Mon Jul 11, 2022 3:58 am by Tommy Monk
» More evidence of remoaners still trying to overturn Brexit... and this is a conservative MP who should be drummed out of the party and out of parliament!
Sun Jul 10, 2022 10:50 pm by Tommy Monk
» R Kelly 30 years, Ghislaine Maxwell 20 years... but here in UK...
Fri Jul 08, 2022 5:31 pm by Original Quill